GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grand Pharmaceutical Group Ltd (HKSE:00512) » Definitions » 3-Year EPS without NRI Growth Rate

Grand Pharmaceutical Group (HKSE:00512) 3-Year EPS without NRI Growth Rate : 9.10% (As of Dec. 2023)


View and export this data going back to 1995. Start your Free Trial

What is Grand Pharmaceutical Group 3-Year EPS without NRI Growth Rate?

Grand Pharmaceutical Group's EPS without NRI for the six months ended in Dec. 2023 was HK$0.29.

During the past 12 months, Grand Pharmaceutical Group's average EPS without NRI Growth Rate was -0.80% per year. During the past 3 years, the average EPS without NRI Growth Rate was 9.10% per year. During the past 5 years, the average EPS without NRI Growth Rate was 17.90% per year. During the past 10 years, the average EPS without NRI Growth Rate was 31.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Grand Pharmaceutical Group was 56.30% per year. The lowest was -10.70% per year. And the median was 31.55% per year.


Competitive Comparison of Grand Pharmaceutical Group's 3-Year EPS without NRI Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Grand Pharmaceutical Group's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Grand Pharmaceutical Group's 3-Year EPS without NRI Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Grand Pharmaceutical Group's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Grand Pharmaceutical Group's 3-Year EPS without NRI Growth Rate falls into.



Grand Pharmaceutical Group 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Grand Pharmaceutical Group  (HKSE:00512) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Grand Pharmaceutical Group 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Grand Pharmaceutical Group's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Grand Pharmaceutical Group (HKSE:00512) Business Description

Traded in Other Exchanges
Address
99 Queen's Road, Units 3302, 33rd Floor, The Center, Central, Hong Kong, HKG
Grand Pharmaceutical Group Ltd, formerly China Grand Pharmaceutical and Healthcare Holdings Ltd is a drug manufacturer. The company through its subsidiaries manufactures and sells pharmaceutical preparations and medical devices, biotechnology products, nutrition products, specialized pharmaceutical raw materials, and other products. Geographically, it derives a majority of revenue from China and also has a presence in America; Europe; Asia other than the PRC and others.

Grand Pharmaceutical Group (HKSE:00512) Headlines

No Headlines